GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Integrated Primary Care: A Path to Better Mental Health
Integrating behavioral health into regular doctor's visits is a game-changer for how we think about and receive mental healthcare. Imagine going to your family doctor for a sore throat, and during that same visit, you can also talk to someone about feeling stressed or anxious. This idea, called Integrated Primary Care (IPC), aims to bring together physical and mental health services under one roof.
Bridging the Gap: Understanding Digital Mental Health Tools in Everyday Healthcare
Mental health is a crucial part of our overall well-being, yet for many people, especially those in underserved communities, getting the right mental health care can be incredibly difficult. They might face numerous obstacles, like a lack of local specialists, high costs, or the stigma often associated with seeking mental health support. This is where Integrated Primary Care (IPC) settings come into play.
Triumphant Return: Judge Orders FDA to Restore Vital Clinical Trial Diversity Webpages, Empowering Health Equity!
It is a truly hopeful and significant development in the realm of healthcare and government transparency that a US District Judge has recently ordered the full reinstatement of crucial healthcare resources, including vital webpages dedicated to clinical trial diversity, by the US Food and Drug Administration (FDA) and the Department of Health and Human Services
Stay Steady, Stay Safe: The Ultimate Guide to Preventing Falls and Fractures as You Age
For many older adults, a simple everyday mishap—like slipping on a wet floor or tripping over a rug—can instantly become a life-altering event. Falls are not just common; they are a significant threat to long-term health, mobility, and independence. Every year, thousands of older adults experience broken bones due to falls.
The $17 Billion Race: Why New Treatments for Alzheimer’s Disease Are Changing the Game
The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action. Experts are encouraged to see a broader range of therapeutic options emerging in the pipeline for patients.
A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything
The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.
Remote Relief: How Virtual Support Boosts Mood and Confidence for Families Facing Dementia
Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.
The Titans of Memory: Inside the Top 7 Organizations Fighting Alzheimer’s Disease
Alzheimer’s research in the United States is a massive, multi-billion-dollar ecosystem. It is led by a powerful and highly coordinated mix of federal government agencies, non-profit foundations, and elite academic medical centers.
Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science
When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.
The Missing Link in Alzheimer’s: How a Natural Brain Element Could Be the Key to Reversing Memory Loss
For over thirty years, Bruce Yankner has been at the very forefront of Alzheimer's research. From his early days first proving the devastating toxicity of amyloid plaques in the 1990s, to his current work uncovering the brain's hidden reliance on natural lithium, his scientific journey has been nothing short of remarkable. By finally explaining the elusive missing link
The Silent Challenge of Early Alzheimer’s Detection
Discover how researchers use AI and machine learning algorithms on routine electronic health records to spot early Alzheimer’s risk up to 7 years before symptoms appear.
Demystifying Glassbury AI: Transforming Complex Medical Data into Clear Solutions
Discover how Glassbury AI standardizes complex multi-omic datasets and Electronic Health Records to create reliable, cross-verified clinical AI models in simple, accessible terms.
How AI is Tackling Alzheimer's: Inside C-BRAIN and Karyoptosis Research
Discover how artificial intelligence and global research initiatives like the C-BRAIN Consortium are uniting open-source data to fight neurodegenerative diseases, plus how new discoveries like karyoptosis offer fresh hope for Alzheimer's therapies.
Canine Biomarkers & Trial Overhauls: This Week’s Top Alzheimer’s Discoveries
Explore October 2026 breakthroughs in Alzheimer's research, including Colorado State's canine dementia models, Cleveland Clinic's trial overhaul framework, and new p-tau217 plasma insights.
Beyond the Memory Trap: Simple Blood Tests, Subcut Injections, and Smart Care Tech are Rewriting the Alzheimer’s Story
Explore the latest 2026 Alzheimer’s research updates. Discover how simple blood tests, new home-injection trials, AI healthtech, and modern caregiving strategies are transforming memory care and hospice support.
Beyond the "Black Box": Why Trust is the Ultimate Data Moat in Clinical Trial Recruitment
In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy. At Glassbury, we recognize that a "black box" approach is insufficient for the long-term challenges of Alzheimer's disease and related CNS conditions
The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early
For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors
Why We Can't Sleep in Early Alzheimer's: The New Science of Brain Inflammation
For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain.
Bridging the Gap: How Glassbury AI is Making Medical Research Work for Everyone
At Glassbury AI, we believe health justice starts with inclusion. We are using modern technology to fix this recruitment crisis by building trust and making the process easy to understand for every family.
Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind
There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.